Results 21 to 30 of about 2,678,438 (292)

Association of radiation dose intensity with overall survival in patients with distant metastases

Cancer Medicine, 2021
Background Patients with metastatic cancer referred to radiation oncology have diverse prognoses and there is significant interest in personalizing treatment.
Johnny Kao, Mark K. Farrugia, Samantha Frontario, Amanda Zucker, Emily Copel, John Loscalzo, Ashish Sangal, Boramir Darakchiev, Anurag Singh, Symeon Missios   +9 more
doaj   +1 more source

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies

Clinical and Translational Medicine, 2022
Background The CD47‐signal regulatory protein alpha (SIRPα) ‘don't eat me’ signalling axis is perhaps the most prominent innate immune checkpoint to date.
Renée Bouwstra, Tom vanMeerten, Edwin Bremer   +2 more
doaj   +1 more source

Adverse outcomes in nontrial like patients on commercial HeartMate 3 LVAD support

JHLT Open, 2023
Background: Patient selection for real-world use of HeartMate 3 left ventricular assist device (HM3 LVAD) differs from that of clinical trials. We assessed adverse-event rates between “nontrial like” (NTL) and “trial like” (TL) patients who underwent ...
Laura Coyle, APN, Colleen Gallagher, BSN, Nicole Graney, APN, Lisa Kukla, APN, Robin Paliga, APN, Kylie Hughes, APN, Rachel Pedersen, BA, Kathleen Schultz, APN, Adam JT Schuldt, MD, PhD, Nasir Sulemanjee, MD, Gregory P. Macaluso, MD, Sunil Pauwaa, MD, James Monaco, MD, Mark Dela Cruz, MD, William G. Cotts, MD, Nikhil Narang, MD, Patroklos S. Pappas, MD, Antone J. Tatooles, MD, Vinh Q. Chau, MD   +18 more
doaj   +1 more source

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations. [PDF]

, 2017
Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel.
Hoffman-Censits, Jean, Patel, Sheel
core   +3 more sources

A Tractography-Based Grading Scale of Brain Arteriovenous Malformations Close to the Corticospinal Tract to Predict Motor Outcome After Surgery

Frontiers in Neurology, 2019
Background: Surgical decision-making for brain arteriovenous malformations (AVMs) close to the corticospinal tract (CST) is always challenging. The purpose of this study was to develop a tractography-based grading scale to improve preoperative risk ...
Maogui Li, Maogui Li, Maogui Li, Maogui Li, Pengjun Jiang, Pengjun Jiang, Pengjun Jiang, Pengjun Jiang, Rui Guo, Rui Guo, Rui Guo, Rui Guo, Qingyuan Liu, Qingyuan Liu, Qingyuan Liu, Qingyuan Liu, Shuzhe Yang, Shuzhe Yang, Shuzhe Yang, Shuzhe Yang, Jun Wu, Jun Wu, Jun Wu, Jun Wu, Yong Cao, Yong Cao, Yong Cao, Yong Cao, Shuo Wang, Shuo Wang, Shuo Wang, Shuo Wang   +31 more
doaj   +1 more source

Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy - a single center prospective cohort

Frontiers in Oncology, 2023
BackgroundThe role of stereotactic ablative radiation therapy (SABR) as local treatment option after chemotherapy for locally advanced pancreatic cancer (LAPC) is evolving.
D. Doppenberg, D. Doppenberg, D. Doppenberg, F. J. Lagerwaard, F. J. Lagerwaard, S. van Dieren, M. R. Meijerink, M. R. Meijerink, J. J. van der Vliet, J. J. van der Vliet, J. J. van der Vliet, M. G. Besselink, M. G. Besselink, G. van Tienhoven, G. van Tienhoven, E. Versteijne, E. Versteijne, B. J. Slotman, B. J. Slotman, J. W. Wilmink, J. W. Wilmink, G. Kazemier, G. Kazemier, A. M. E. Bruynzeel, A. M. E. Bruynzeel   +24 more
doaj   +1 more source

The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [PDF]

, 2017
Background: Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic
Abdel-Rahman, Aguiar, Borghaei, Brahmer, Calhoun, Chen, Dent, Domingues, Doyle, Ferlay, Goeree, Hanahan, Herbst, Herbst, Huang, Hurvitz, Masters, Matter-walstra, Moro-Sibilot, Nafees, Passiglia, Petitti, Rittmeyer, Siegel, Stokes, Tartari   +25 more
core   +3 more sources

Mapping MAGE-A4 expression in solid cancers for targeted therapies

Frontiers in Oncology
Melanoma-associated antigen A4 (MAGE-A4) is a promising target for anticancer therapy. However, limited contemporary data are available on the details of MAGE-A4 protein expression in different cancer types.
Christin Habigt, Sylvie Rottey, Iben Spanggaard, Juanita S. Lopez, Elena Garralda, Emiliano Calvo, Oliver Bechter, Oliver Bechter, Jayesh Desai, Rachel Galot, Leena Gandhi, Florian Heil, Natascha Rieder, Ivan Dimitrov, Iris Martinez Quetglas, Christian Heichinger, Nino Keshelava, Andreas Roller   +17 more
doaj   +1 more source

Is There a Place for Somatostatin Analogues for the Systemic Treatment of Hepatocellular Carcinoma in the Immunotherapy Era?

Livers, 2022
Patients with advanced hepatocellular carcinoma (HCC) have a very limited survival rate even after the recent inclusion of kinase inhibitors or immune checkpoint inhibitors in the therapeutic armamentarium. A significant problem with the current proposed
Elias Kouroumalis, Ioannis Tsomidis, Argryro Voumvouraki   +2 more
doaj   +1 more source

Adherence to Tuberculosis Therapy among Patients Receiving Home-Based Directly Observed Treatment: Evidence from the United Republic of Tanzania. [PDF]

, 2012
\ud \ud Non-adherence to tuberculosis (TB) treatment is the leading contributor to the selection of drug-resistant strains of Mycobacterium tuberculosis and subsequent treatment failure.
A Girma, A Jaiswal, A Kebede, Abdallah Mkopi, Alexander Schulze, BS Uzochukwu, Cesar V. Munayco, D Werb, Eveline Geubbels, F Lwilla, Frank van Leth, Fred Lwilla, GJ Churchyard, H Getahun, HJ Chum, J van den Boogaard, J van den Boogaard, JH Wagner, JL Johnson, JN Newell, K Okanurak, K Peltzer, MA Khan, MG Amuha, MG Amuha, NP Mqoqi, Nyagosya Range, P Garner, RB Chimzizi, RL Guerra, RM Kaiser, S Egwaga, SA Munro, Saidi Egwaga, SO Olayemi, TM Chonde, WM El-Sadr, Z Zvavamwe   +37 more
core   +3 more sources